| Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology AT Gerds, J Gotlib, H Ali, P Bose, A Dunbar, A Elshoury, TI George, ... Journal of the National Comprehensive Cancer Network 20 (9), 1033-1062, 2022 | 66 | 2022 |
| Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma X Zhan, W Yu, R Franqui-Machin, ML Bates, K Nadiminti, H Cao, ... Oncotarget 8 (67), 111213, 2017 | 47 | 2017 |
| Identification and characterization of tumor-initiating cells in multiple myeloma M Gao, H Bai, Y Jethava, Y Wu, Y Zhu, Y Yang, J Xia, H Cao, ... JNCI: Journal of the National Cancer Institute 112 (5), 507-515, 2020 | 43 | 2020 |
| Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation X You, F Liu, M Binder, A Vedder, T Lasho, Z Wen, X Gao, E Flietner, ... Blood, The Journal of the American Society of Hematology 139 (7), 1066-1079, 2022 | 34 | 2022 |
| Mean platelet volume does not predict risk of myocardial infarction or coronary artery disease in Indian patients S Damodar, KV Ganesh, S Murthy Platelets 19 (1), 80-81, 2008 | 19 | 2008 |
| Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma K Nadiminti, MH Sidiqi, K Meleveedu, HB Alkhateeb, WJ Hogan, M Litzow, ... Blood cancer journal 11 (3), 63, 2021 | 16 | 2021 |
| Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function MH Sidiqi, K Nadiminti, AS Al Saleh, K Meleveedu, FK Buadi, ... Bone Marrow Transplantation 54 (11), 1775-1779, 2019 | 15 | 2019 |
| Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma KKS Abbi, M Silverman, U Farooq, A Tricot, L Dozeman, K Nadiminti, ... British journal of haematology 174 (4), 536-540, 2016 | 15 | 2016 |
| Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology NJ Hess, DP Turicek, J Riendeau, SJ McIlwain, E Contreras Guzman, ... Science Advances 9 (12), eadf0567, 2023 | 13 | 2023 |
| The Composite Health Risk Assessment Model (CHARM) to predict 1-year non-relapse mortality (NRM) among older recipients of allogeneic transplantation: A prospective BMT-CTN … A Artz, BR Logan, W Saber, N Geller, A Bellach, J Kou, W Wood, ... Blood 142, 109, 2023 | 10 | 2023 |
| PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia KS Meleveedu, D Chen, K Nadiminti, H Sidiqi, S Khan, H Alkhateeb, ... Leukemia & Lymphoma 62 (3), 764-767, 2021 | 10 | 2021 |
| Cytogenetics and chromosomal abnormalities in multiple myeloma–A review K Nadiminti, F Zhan, G Tricot Clon Transgen 2 (114), 2, 2013 | 10 | 2013 |
| VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma K Nadiminti, KK Singh Abbi, SL Mott, L Dozeman, A Tricot, A Schultz, ... OncoTargets and therapy, 217-226, 2017 | 8 | 2017 |
| A single autologous stem cell transplant (ASCT) followed by two years of post-transplant therapy in recently diagnosed elderly multiple myeloma (MM) patients. Safety and … K Nadiminti, C Strouse, P Vikas, L Dozeman, A Schultz, G Berns, J Claus, ... Blood 132, 2153, 2018 | 7 | 2018 |
| Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration T Jain, HL Tsai, H Elmariah, P Vachhani, T Karantanos, SA Wall, ... Haematologica 108 (12), 3321, 2023 | 4 | 2023 |
| t (15; 17) associated with primary myelofibrosis: a case report of an unusual clinical presentation and diagnostic dilemma K Nadiminti, M Silverman, S Bhagavathi, P Vikas OncoTargets and therapy, 5449-5455, 2019 | 4 | 2019 |
| Impact of chemotherapy based induction using dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide (DPACE) versus novel agent induction in patients undergoing … K Nadiminti, C Strouse, MH Sidiqi, L Dozeman, SL Mott, A Schultz, ... Biology of Blood and Marrow Transplantation 25 (3), S399-S400, 2019 | 4 | 2019 |
| A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice A Rajagopalan, Y Feng, MB Gayatri, EA Ranheim, T Klungness, ... The Journal of Clinical Investigation 133 (24), 2023 | 3 | 2023 |
| Incidence of fungal infections associated with the use of novel agents as part of conditioning regimen during autologous stem cell transplant in multiple myeloma; a single … K Nadiminti, SV Pilla, KKS Abbi, A Tricot, A Schultz, L Dozeman, SL Mott, ... Biology of Blood and Marrow Transplantation 23 (3), S193, 2017 | 3 | 2017 |
| Intraocular bevacizumab in the treatment of choroidal metastases from breast cancer K Nadiminti, JP Leone Case Reports 2016, bcr2016215719, 2016 | 3 | 2016 |
kamal kant abbiAssistant Professsor, University of Iowa Hospitals and clinics在 uiowa.edu 的电子邮件经过验证
kamal kant abbiAssistant Professsor, University of Iowa Hospitals and clinics在 uiowa.edu 的电子邮件经过验证